Brief: Rubius Therapeutics Highlights Preclinical Data At The American Society Of Gene & Cell Therapy 23Rd Annual Meeting For Rtx-321, An Oncology Product Candidate For Hpv-Positive Cancers
12/05/2020 11:07
May 12 (Reuters) - Rubius Therapeutics Inc RUBY.O :
* RUBIUS THERAPEUTICS HIGHLIGHTS PRECLINICAL DATA FOR
RTX-321, A
RED CELL THERAPEUTIC™ ONCOLOGY PRODUCT CANDIDATE FOR
HPV-POSITIVE CANCERS, AT THE AMERICAN SOCIETY OF GENE & CELL
THERAPY 23RD ANNUAL MEETING
Source text for Eikon: ID:nGNX6tdN0B
Further company coverage: RUBY.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rubius Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Apple, TCR2 Therapeutics, Silvergate Capital
Brief: Rubius Therapeutics Inc - Nasdaq Notified Co That Trading In Co's Stock Will Be Suspended Upon Opening Of Business On March 7, 2023
Brief: Rubius Therapeutics Board Of Directors Approved Plan Of Liquidation And Dissolution Of Company
Rubius Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Baidu, Boeing, Microsoft